Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ABT stock price vs REGN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at REGN's multiple
Needs Annual EPS, REGN P/E.
Implied fair value · at ABT's multiple
Needs Annual EPS, ABT P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ABBOTT LABORATORIES · implied price per share
Reporting currency could not be verified.
REGENERON PHARMACEUTICALS, INC. · implied price per share
Reporting currency could not be verified.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
ABT · not enough data.
REGN · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Johnson & Johnson
ABT vs JNJ
Medtronic plc
ABT vs MDT
BECTON DICKINSON & CO
ABT vs BDX
Thermo Fisher Scientific Inc.
ABT vs TMO
DANAHER CORP /DE/
ABT vs DHR
BOSTON SCIENTIFIC CORP
ABT vs BSX
AMGEN INC
ABT vs AMGN
PFIZER INC
ABT vs PFE
BRISTOL MYERS SQUIBB CO
ABT vs BMY
BIOGEN INC.
ABT vs BIIB
GILEAD SCIENCES, INC.
ABT vs GILD
Seagate Technology Holdings plc
ABT vs STX
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ABT can re-rate toward the historical band without a valuation de-rating, then hold or accumulate selectively; otherwise, the data favor trimming because ABT trades above REGN-implied and DCF value while REGN shows better profitability and lower leverage.
ABT is trading above REGN-implied valuation range midpoint and well above the DCF range, with the current price of $88.18 versus an implied price of $54.90 indicating a 37.7% downside. The gap appears driven more by valuation normalization than by a collapse in fundamentals, since ABT still has stronger revenue growth than REGN but trades at a richer P/E.
Supporting Metrics
